These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24373090)

  • 21. Influence of selected HLA tissue compatibility antigens on the course and efficacy of viral hepatitis C treatment--actual knowledge position.
    Łoś-Rycharska E; Szaflarska-Popławska A
    Adv Med Sci; 2009; 54(1):14-9. PubMed ID: 19482730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 23. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract]   [Full Text] [Related]  

  • 24. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
    Main J
    J Hepatol; 1995; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon for hepatitis C: where it has been and where it is going.
    Koretz RL
    Immunotherapy; 2013 Jul; 5(7):673-5. PubMed ID: 23829615
    [No Abstract]   [Full Text] [Related]  

  • 26. New drugs for hepatitis C virus.
    Pockros PJ
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):145-54. PubMed ID: 19072442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1: Summary of California Technology Assessment Forum Report.
    Tice JA; Chahal HS; Ollendorf DA
    JAMA Intern Med; 2015 Sep; 175(9):1559-60. PubMed ID: 26167717
    [No Abstract]   [Full Text] [Related]  

  • 29. Ophthalmological complications in hepatitis C virus infection: side effect of interferon therapy or a direct role of HCV?
    Pazienza V
    Biomed Pharmacother; 2011 Jul; 65(4):317-8. PubMed ID: 21705184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
    Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
    Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Side effects of interferon therapy for chronic hepatitis C].
    Arase Y
    Nihon Rinsho; 2006 Jul; 64(7):1363-7. PubMed ID: 16838657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New therapeutic strategies for hepatitis C.
    Di Bisceglie AM; McHutchison J; Rice CM
    Hepatology; 2002 Jan; 35(1):224-31. PubMed ID: 11786980
    [No Abstract]   [Full Text] [Related]  

  • 34. The experience of interferon-based treatments for hepatitis C infection.
    Hopwood M; Treloar C
    Qual Health Res; 2005 May; 15(5):635-46. PubMed ID: 15802540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluating the efficacy of interferon therapy on hepatitis C patients].
    Shiraha H; Iwasaki Y; Shiratori Y
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):489-92. PubMed ID: 15359847
    [No Abstract]   [Full Text] [Related]  

  • 36. [HCV genotype as a predictor of response to IFN therapy in chronic hepatitis C].
    Ebata M; Fukuda Y; Koyama Y; Hayakawa T; Kumada T; Nakano S
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):954-8. PubMed ID: 7563909
    [No Abstract]   [Full Text] [Related]  

  • 37. Interferons: Success in anti-viral immunotherapy.
    Lin FC; Young HA
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):369-76. PubMed ID: 25156421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus: prospects for future therapies.
    Wilkinson T
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of acute hepatitis C].
    García Compeán D
    Rev Gastroenterol Mex; 2002 Oct; 67 Suppl 2():S61-6. PubMed ID: 12712857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti HCV drugs--ribavirin, telaprevir].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2012 Apr; 70(4):614-9. PubMed ID: 22568142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.